Archive

The Octopus PortfolioThe Octopus Portfolio
#3 The Journey of Compounding - 2024 Letter to Readers

#3 The Journey of Compounding - 2024 Letter to Readers

2024 Annual Review to all The Octopus Value Investing readers

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
CagriSema Phase III Results Review

CagriSema Phase III Results Review

Novo Nordisk Stock Plunge: Overreaction or Justified?

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
What Does It Mean for a Drug to Be Regulatory Approved?

What Does It Mean for a Drug to Be Regulatory Approved?

The Differential Quality of Regulatory Approved Drugs

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
Hims&Hers Health: My Take

Hims&Hers Health: My Take

My Rationale to Drop Hims&Hers Health Investment Case

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+3+3
Q3 2024 Earnings Recap

Q3 2024 Earnings Recap

Earnings Review Compilation of Novo Nordisk, Pandora & Lonza AG

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#2 Schott Pharma AG - Quantitative Analysis

#2 Schott Pharma AG - Quantitative Analysis

Looking into the fundamentals of the pharma glass packaging leader

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#1 Schott Pharma - Qualitative Analysis

#1 Schott Pharma - Qualitative Analysis

Insights on the Pharmaceutical Glass Packaging Leader

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
Comparing the Pharmaceutical Glass Packaging Players

Comparing the Pharmaceutical Glass Packaging Players

Digging into Schott Pharma AG, Gerresheimer AG and Stevanato Group fundamentals

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
Novo Nordisk September 2024 recap

Novo Nordisk September 2024 recap

An hectic month for the Danish company

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
Understanding NASH/MASH

Understanding NASH/MASH

Uncovering the potential behind Novo Nordisk's optionality

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
#4 Sectors in Brief - Players in the Pharmaceutical Glass Packaging Segment

#4 Sectors in Brief - Players in the Pharmaceutical Glass Packaging Segment

Pinpointing Prominent Sector Players

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+1+1
Pandora A/S - H1 2024 Earnings Review

Pandora A/S - H1 2024 Earnings Review

The affordable luxury market defies pure luxury slowdown

The Octopus Value Investing
The Octopus Value Investing
FirstBack
1234
Next Last